Guerbet 2014 annual revenue: EU411.6M (+ 5.6%) at constant exchange rates

> Fourth-quarter revenue : €106.4M, +4.3% at constant exchange rates
> Annual profitability target confirmed

VILLEPINTE, France, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Guerbet (FR0000032526 GBT), a global specialist in contrast agents for medical imaging, is publishing annual revenue for 2014 of €409.0M, representing a 4.9% increase. Excluding exchange rate effects, the annual revenue stands at €411.6M, growing by 5.6%, in line with the guidance.

Consolidated (IFRS) revenue at 31 December

In millions of Euros 2014 2013 Change (%)
First-quarter 96.6 91.0 6.1%
Second-quarter 106.1 101.4 4.6%
Third-quarter 99.9 96.0 4.0%
Fourth-quarter 106.4 101.3 5.1%
Total 409.0 389.7 4.9%
Of which Europe 289.3 274.5 5.4%
Of which Other Markets 119.7 115.2 3.9%

Contribution to growth from all the geographies in the fourth quarter

Fourth-quarter revenue totals €106.4M, rising by 5.1% (+4.3% at constant exchange rates). Sales in Europe (+6.3%) and in Other Markets (+2.3%) were driven particularly by the MRI segment (+10.1%) and especially by Dotarem® in the US.

The 4 business segments grew in 2014

Full-year sales in the MRI segment (€168.3M in 2014) were strong. Despite the adverse effect of an inventory build-up in Germany, the level of activity was 3.0% higher. Dotarem® was also rolled out in the US with strong year-end sales growth and a broadening of the customer base.

In the X-Ray segment (€187.9M in 2014), revenue rose slightly versus 2013 (+1.1%), thanks particularly to sales of Xenetix®. The new ScanBag® by Xenetix filling line in Aulnay should reach its expected production rate as of the second half of 2015. This delay will have a one-off impact on this activity's sales and margins in the first half of 2015.

The Group's other growth platforms (Interventional Radiology, Medical Devices, USA and China) performed well, as expected, recording 25% growth in 2014. The IRT segment exceeded the target of €30M revenue over the year, while in the Medical Devices segment, the FlowSens® injector lived up to the success of its commercial launch.

Guerbet confirms its profit guidance, of an operating margin between 9% and 10% (current operating income / reported sales), on the strength of this solid commercial performance.

Upcoming events

  • Publication of the 2014 annual results on 12 March 2015 before trading

About Guerbet

Guerbet is a pioneer in the contrast agent field, with more than 80 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnostic and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 10% of its sales each year. Guerbet (GBT) is listed on NYSE Euronext Paris (Segment B - Mid Caps) and generated revenue of €390 million in 2013. It has a total workforce of 1,485 employees, 1,000 of whom are based in France.
For further information about Guerbet, please go to


Guerbet Actifin
Jean-François Le Martret
Chief Financial Officer
01 45 91 50 00

Nicolas Meunier/Benjamin Lehari
01 56 88 11 11

Jennifer Jullia
01 56 88 11 19

Press release